sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
CAR-T Cell Therapy Market, By Drug Indication (Axicabtagene Ciloleucel (Yescarta), Brexucabtagene Autoleucel (Tecartus), Ciltacabtagene Autoleucel (Carvykti), Idecabtagene Vicleucel (Abecma), Lisocabtagene Maraleucel (Breyanzi), Tisagenlecleucel (Kymriah)

CAR-T Cell Therapy Market, By Drug Indication (Axicabtagene Ciloleucel (Yescarta),...

Home / Categories / Healthcare
CAR-T Cell Therapy Market, By Drug Indication (Axicabtagene Ciloleucel (Yescarta), Brexucabtagene Autoleucel (Tecartus), Ciltacabtagene Autoleucel (Carvykti), Idecabtagene Vicleucel (Abecma), Lisocabtagene Maraleucel (Breyanzi), Tisagenlecleucel (Kymriah)
CAR-T Cell Therapy Market, By...
Report Code
RO1/128/1292

Publish Date
25/Nov/2024

Pages
200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. Global CAR-T Cell Therapy Market Insights
3.1. End User Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Rising prevalence of cancer
3.2.1.2. Continuous advancements in cell engineering and genetic modification techniques
3.2.1.3. Favorable regulatory landscape: for CAR-T cell therapy
3.2.1.4. Growing interest from pharmaceutical companies, biotech firms, and investors
3.2.2. Restraints
3.2.2.1. High costs of CAR-T cell therapy
3.2.2.2. Limited availability and access to CAR-T cell therapy is often restricted to a limited number of patients.
3.2.2.3. Potential side effects associated with CAR-T cell therapy
3.2.3. Opportunities
3.2.3.1. Expansion into new indications
3.2.3.2. Combining CAR-T cell therapy with other treatments
3.2.3.3. Advancements in genomics and personalized medicine
3.2.4. Challenges
3.2.4.1. Manufacturing challenges associated with the production of CAR-T cell therapies
3.2.4.2. Ensuring adequate reimbursement for CAR-T cell therapy
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. Global CAR-T Cell Therapy Market: Marketing Strategies
5. Global CAR-T Cell Therapy Market: Pricing Analysis
6. Global CAR-T Cell Therapy Market: Geography Analysis
6.1. Global CAR-T Cell Therapy Market, Geographical Analysis, 2023
6.2. Global CAR-T Cell Therapy, Market Attractiveness Analysis, 2024-2030
7. Global CAR-T Cell Therapy Market Overview
7.1. Market Size & Forecast, 2019-2030
7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
7.2.1. By Drug Indication
7.2.1.1. Axicabtagene Ciloleucel (Yescarta)
7.2.1.2. Brexucabtagene Autoleucel (Tecartus)
7.2.1.3. Ciltacabtagene Autoleucel (Carvykti)
7.2.1.4. Idecabtagene Vicleucel (Abecma)
7.2.1.5. Lisocabtagene Maraleucel (Breyanzi)
7.2.1.6. Tisagenlecleucel (Kymriah)
7.2.1.7. Others
7.2.2. By Indication
7.2.2.1. Acute Lymphoblastic Leukemia
7.2.2.2. Non-Hodgkin Lymphoma
7.2.2.3. Multiple Myeloma
7.2.3. By End User
7.2.3.1. Hospitals
7.2.3.2. Oncology Treatment Centers
7.2.4. By Region
7.2.4.1. North America
7.2.4.2. Europe
7.2.4.3. Asia Pacific (APAC)
7.2.4.4. Latin America (LATAM)
7.2.4.5. Middle East and Africa (MEA)
8. North America CAR-T Cell Therapy Market
8.1. Market Size & Forecast, 2019-2030
8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
8.2.1. By Drug Indication
8.2.2. By Indication
8.2.3. By End User
8.2.4. By Country
8.2.4.1. United States
8.2.4.1.1. By Drug Indication
8.2.4.1.2. By Indication
8.2.4.1.3. By End User
8.2.4.2. Canada
8.2.4.2.1. By Drug Indication
8.2.4.2.2. By Indication
8.2.4.2.3. By End User
9. Europe CAR-T Cell Therapy Market
9.1. Market Size & Forecast, 2019-2030
9.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
9.2.1. By Drug Indication
9.2.2. By Indication
9.2.3. By End User
9.2.4. By Country
9.2.4.1. Germany
9.2.4.1.1. By Drug Indication
9.2.4.1.2. By Indication
9.2.4.1.3. By End User
9.2.4.2. United Kingdom
9.2.4.2.1. By Drug Indication
9.2.4.2.2. By Indication
9.2.4.2.3. By End User
9.2.4.3. Italy
9.2.4.3.1. By Drug Indication
9.2.4.3.2. By Indication
9.2.4.3.3. By End User
9.2.4.4. France
9.2.4.4.1. By Drug Indication
9.2.4.4.2. By Indication
9.2.4.4.3. By End User
9.2.4.5. Spain
9.2.4.5.1. By Drug Indication
9.2.4.5.2. By Indication
9.2.4.5.3. By End User
9.2.4.6. Belgium
9.2.4.6.1. By Drug Indication
9.2.4.6.2. By Indication
9.2.4.6.3. By End User
9.2.4.7. Russia
9.2.4.7.1. By Drug Indication
9.2.4.7.2. By Indication
9.2.4.7.3. By End User
9.2.4.8. The Netherlands
9.2.4.8.1. By Drug Indication
9.2.4.8.2. By Indication
9.2.4.8.3. By End User
9.2.4.9. Rest of Europe
9.2.4.9.1. By Drug Indication
9.2.4.9.2. By Indication
9.2.4.9.3. By End User
10. Asia Pacific CAR-T Cell Therapy Market
10.1. Market Size & Forecast, 2019-2030
10.1.1. By Value (USD Billion)
10.2. Market Share & Forecast
10.2.1. By Drug Indication
10.2.2. By Indication
10.2.3. By End User
10.2.4. By Country
10.2.4.1. China
10.2.4.1.1. By Drug Indication
10.2.4.1.2. By Indication
10.2.4.1.3. By End User
10.2.4.2. India
10.2.4.2.1. By Drug Indication
10.2.4.2.2. By Indication
10.2.4.2.3. By End User
10.2.4.3. Japan
10.2.4.3.1. By Drug Indication
10.2.4.3.2. By Indication
10.2.4.3.3. By End User
10.2.4.4. South Korea
10.2.4.4.1. By Drug Indication
10.2.4.4.2. By Indication
10.2.4.4.3. By End User
10.2.4.5. Australia & New Zealand
10.2.4.5.1. By Drug Indication
10.2.4.5.2. By Indication
10.2.4.5.3. By End User
10.2.4.6. Indonesia
10.2.4.6.1. By Drug Indication
10.2.4.6.2. By Indication
10.2.4.6.3. By End User
10.2.4.7. Malaysia
10.2.4.7.1. By Drug Indication
10.2.4.7.2. By Indication
10.2.4.7.3. By End User
10.2.4.8. Singapore
10.2.4.8.1. By Drug Indication
10.2.4.8.2. By Indication
10.2.4.8.3. By End User
10.2.4.9. Vietnam
10.2.4.9.1. By Drug Indication
10.2.4.9.2. By Indication
10.2.4.9.3. By End User
10.2.4.10. Rest of APAC
10.2.4.10.1. By Drug Indication
10.2.4.10.2. By Indication
10.2.4.10.3. By End User
11. Latin America CAR-T Cell Therapy Market
11.1. Market Size & Forecast, 2019-2030
11.1.1. By Value (USD Billion)
11.2. Market Share & Forecast
11.2.1. By Drug Indication
11.2.2. By Indication
11.2.3. By End User
11.2.4. By Country
11.2.4.1. Brazil
11.2.4.1.1. By Drug Indication
11.2.4.1.2. By Indication
11.2.4.1.3. By End User
11.2.4.2. Mexico
11.2.4.2.1. By Drug Indication
11.2.4.2.2. By Indication
11.2.4.2.3. By End User
11.2.4.3. Argentina
11.2.4.3.1. By Drug Indication
11.2.4.3.2. By Indication
11.2.4.3.3. By End User
11.2.4.4. Peru
11.2.4.4.1. By Drug Indication
11.2.4.4.2. By Indication
11.2.4.4.3. By End User
11.2.4.5. Rest of LATAM
11.2.4.5.1. By Drug Indication
11.2.4.5.2. By Indication
11.2.4.5.3. By End User
12. Middle East and Africa CAR-T Cell Therapy Market
12.1. Market Size & Forecast, 2019-2030
12.1.1. By Value (USD Billion)
12.2. Market Share & Forecast
12.2.1. By Drug Indication
12.2.2. By Indication
12.2.3. By End User
12.2.4. By Country
12.2.4.1. Saudi Arabia
12.2.4.1.1. By Drug Indication
12.2.4.1.2. By Indication
12.2.4.1.3. By End User
12.2.4.2. UAE
12.2.4.2.1. By Drug Indication
12.2.4.2.2. By Indication
12.2.4.2.3. By End User
12.2.4.3. Qatar
12.2.4.3.1. By Drug Indication
12.2.4.3.2. By Indication
12.2.4.3.3. By End User
12.2.4.4. Kuwait
12.2.4.4.1. By Drug Indication
12.2.4.4.2. By Indication
12.2.4.4.3. By End User
12.2.4.5. South Africa
12.2.4.5.1. By Drug Indication
12.2.4.5.2. By Indication
12.2.4.5.3. By End User
12.2.4.6. Nigeria
12.2.4.6.1. By Drug Indication
12.2.4.6.2. By Indication
12.2.4.6.3. By End User
12.2.4.7. Algeria
12.2.4.7.1. By Drug Indication
12.2.4.7.2. By Indication
12.2.4.7.3. By End User
12.2.4.8. Rest of MEA
12.2.4.8.1. By Drug Indication
12.2.4.8.2. By Indication
12.2.4.8.3. By End User
13. Competitive Landscape
13.1. List of Key Players and Their Offerings
13.2. Global CAR-T Cell Therapy Company Market Share Analysis, 2023
13.3. Competitive Benchmarking, By Operating Parameters
13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
14. Impact of Escalating Geopolitical Tensions on Global CAR-T Cell Therapy Market
15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
15.1. Bristol-Myers Squibb
15.2. Sorrento Therapeutics, Inc.
15.3. Celgene Corporation
15.4. Merck & Co., Inc.
15.5. Novartis AG
15.6. Celyad Oncology
15.7. Juno Therapeutics, Inc.
15.8. Autolus Therapeutics
15.9. Cellectis
15.10. Miltenyi Biotech
15.11. Intellia Therapeutics
15.12. Pfizer, Inc.
15.13. Other Prominent Players
16. Key Strategic Recommendations
17. Research Methodology
17.1. Qualitative Research
17.1.1. Primary & Secondary Research
17.2. Quantitative Research
17.3. Market Breakdown & Data Triangulation
17.3.1. Secondary Research
17.3.2. Primary Research
17.4. Breakdown of Primary Research Respondents, By Region
17.5. Assumptions & Limitations
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com